Clinical Significance of MET Gene Copy Number in Patients with Curatively Resected Gastric Cancer
- Author:
Byung Woog KANG
1
;
Jong Gwang KIM
;
Heyoung PARK
;
Bo Eun PARK
;
Seong Woo JEON
;
Han Ik BAE
;
Oh Kyoung KWON
;
Ho Young CHUNG
;
Wansik YU
Author Information
- Publication Type:Original Article
- Keywords: MET; Stomach neoplasms; Chemotherapy, Adjuvant; Prognosis
- MeSH: Chemotherapy, Adjuvant; Cisplatin; Follow-Up Studies; Gene Dosage; Humans; Multivariate Analysis; Pilot Projects; Prognosis; Real-Time Polymerase Chain Reaction; Stomach Neoplasms; Survival Rate
- From:Chonnam Medical Journal 2015;51(2):81-85
- CountryRepublic of Korea
- Language:English
- Abstract: The present study analyzed the prognostic impact of MET gene copy number in patients with curatively resected gastric cancer who received a combination regimen of cisplatin and S-1. The MET gene copy number was analyzed by use of quantitative real-time polymerase chain reaction. From January 2006 to July 2010, 70 tumor samples from 74 patients enrolled in a pilot study were analyzed. According to a cutoff MET gene copy number of > or =2 copies, a high MET gene copy number was observed in 38 patients (54.3%). The characteristics of the 2 groups divided according to MET gene copy number were similar. With a median follow-up duration of 26.4 months (range, 2.6-73.2 months), the estimated 3-year relapse-free survival and overall survival rates were 54.3% and 77.4%, respectively. No significant association was observed between the MET gene copy number and survival in a multivariate analysis. The MET gene copy number investigated in this study was not found to be associated with prognosis in patients with curatively resected gastric cancer.
